FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma

Science Signaling

Volumn 8, Issue 362, 2015, Pages

  Walker, Matthew P ^a   Stopford, Charles M ^b   Cederlund, Maria ^c   Fang, Fang ^b   Jahn, Christopher ^c   Rabinowitz, Alex D ^a   Goldfarb, Dennis ^d   Graham, David M ^a   Yan, Feng ^a   Deal, Allison M ^e   Fedoriw, Yuri ^a   Richards, Kristy L ^a   Davis, Ian J ^b   Weidinger, Gilbert ^c   Damania, Blossom ^b   Major, Michael B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d Brooks Computer Science Building   (United States)

^e IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BETA CATENIN; BINDING PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; ISOPROTEIN; LIGAND; REPRESSOR PROTEIN; TCF7L2 PROTEIN, HUMAN;

ACETYLATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WNT SIGNALING PATHWAY; ZEBRA FISH; ANIMAL; CANCER TRANSPLANTATION; DIFFUSE LARGE B CELL LYMPHOMA; ENHANCER REGION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEK293 CELL LINE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PROGNOSIS; SCID MOUSE;

DANIO RERIO;

ANIMALS; BETA CATENIN; ENHANCER ELEMENTS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; LIGANDS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MASS SPECTROMETRY; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTEIN ISOFORMS; REPRESSOR PROTEINS; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; WNT PROTEINS; WNT SIGNALING PATHWAY; ZEBRAFISH;

EID: 84922458222     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005654     Document Type: Article

References (84)

1. J. N. Anastas, R. T. Moon, WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013).
2. B. T. MacDonald, K. Tamai, X. He, Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev. Cell 17, 9-26 (2009).
3. S. E. Kim, H. Huang, M. Zhao, X. Zhang, A. Zhang, M. V. Semonov, B. T. MacDonald, J. Garcia Abreu, L. Peng, X. He, Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies. Science 340, 867-870 (2013).
4. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., K. W. Kinzler, Cancer genome landscapes. Science 339, 1546-1558 (2013).
5. P. Polakis, Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 4, a008052 (2012).
6. H. Clevers, R. Nusse, Wnt/β-catenin signaling and disease. Cell 149, 1192-1205 (2012).
7. M. B. Major, B. S. Roberts, J. D. Berndt, S. Marine, J. Anastas, N. Chung, M. Ferrer, X. Yi, C. L. Stoick-Cooper, P. D. vonHaller, L. Kategaya, A. Chien, S. Angers, M.MacCoss, M. A. Cleary, W. T. Arthur, R. T. Moon, New regulators of Wnt/β-catenin signaling revealed by integrative molecular screening. Sci. Signal. 1, ra12 (2008).
8. R. Firestein, A. J. Bass, S. Y. Kim, I. F. Dunn, S. J. Silver, I. Guney, E. Freed, A. H. Ligon, N. Vena, S. Ogino, M. G. Chheda, P. Tamayo, S. Finn, Y. Shrestha, J. S. Boehm, S. Jain, E. Bojarski, C. Mermel, J. Barretina, J. A. Chan, J. Baselga, J. Tabernero, D. E. Root, C. S. Fuchs, M. Loda, R. A. Shivdasani, M. Meyerson, W. C. Hahn, CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 455, 547-551 (2008).
9. J. Rosenbluh, D. Nijhawan, A. G. Cox, X. Li, J. T. Neal, E. J. Schafer, T. I. Zack, X. Wang, A. Tsherniak, A. C. Schinzel, D. D. Shao, S. E. Schumacher, B. A. Weir, F. Vazquez, G. S. Cowley, D. E. Root, J. P. Mesirov, R. Beroukhim, C. J. Kuo, W. Goessling, W. C. Hahn, β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012).
10. F. C. Gonsalves, K. Klein, B. B. Carson, S. Katz, L. A. Ekas, S. Evans, R. Nagourney, T. Cardozo, A. M. Brown, R. DasGupta, An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 108, 5954-5963 (2011).
11. R. DasGupta, A. Kaykas, R. T. Moon, N. Perrimon, Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308, 826-833 (2005).
12. E. Caspi, R. Rosin-Arbesfeld, A novel functional screen in human cells identifies MOCA as a negative regulator of Wnt signaling. Mol. Biol. Cell 19, 4660-4674 (2008).
13. M. Katoh, M. Igarashi, H. Fukuda, H. Nakagama, Cancer genetics and genomics of human FOX family genes. Cancer Lett. 328, 198-206 (2013).
14. H. B. Koon, G. C. Ippolito, A. H. Banham, P. W. Tucker, FOXP1: A potential therapeutic target in cancer. Expert Opin. Ther. Targets 11, 955-965 (2007).
15. M. Gabut, P. Samavarchi-Tehrani, X. Wang, V. Slobodeniuc, D. O'Hanlon, H. K. Sung, M. Alvarez, S. Talukder, Q. Pan, E. O. Mazzoni, S. Nedelec, H. Wichterle, K. Woltjen, T. R. Hughes, P.W. Zandstra, A. Nagy, J. L.Wrana, B. J. Blencowe, An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 147, 132-146 (2011).
16. S. Li, Y.Wang, Y. Zhang, M. M. Lu, F. J. DeMayo, J. D. Dekker, P. W. Tucker, E. E. Morrisey, Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development 139, 2500-2509 (2012).
17. Y. Zhang, S. Li, L. Yuan, Y. Tian, J. Weidenfeld, J. Yang, F. Liu, A. L. Chokas, E. E. Morrisey, Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev. 24, 1746-1757 (2010).
18. A. Sagardoy, J. I. Martinez-Ferrandis, S. Roa, K. L. Bunting, M. A. Aznar, O. Elemento, R. Shaknovich, L. Fontán, V. Fresquet, I. Perez-Roger, E. F. Robles, L. De Smedt, X. Sagaert, A. Melnick, J. A. Martinez-Climent, Downregulation of FOXP1 is required during germinal center B-cell function. Blood 121, 4311-4320 (2013).
19. H. Hu, B. Wang, M. Borde, J. Nardone, S. Maika, L. Allred, P. W. Tucker, A. Rao, Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 7, 819-826 (2006).
20. A. H. Banham, N. Beasley, E. Campo, P. L. Fernandez, C. Fidler, K. Gatter, M. Jones, D. Y. Mason, J. E. Prime, P. Trougouboff, K. Wood, J. L. Cordell, The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 61, 8820-8829 (2001).
21. M. I. Toma, M. Grosser, A. Herr, D. E. Aust, A. Meye, C. Hoefling, S. Fuessel, D. Wuttig, M. P. Wirth, G. B. Baretton, Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10, 634-642 (2008).
22. S. B. Fox, P. Brown, C. Han, S. Ashe, R. D. Leek, A. L. Harris, A. H. Banham, Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor a and improved survival in primary human breast carcinomas. Clin. Cancer Res. 10, 3521-3527 (2004).
23. J. Feng, X. Zhang, H. Zhu, X. Wang, S. Ni, J. Huang, High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am. J. Clin. Pathol. 138, 230-235 (2012).
24. A. H. Banham, J. M. Connors, P. J. Brown, J. L. Cordell, G. Ott, G. Sreenivasan, P. Farinha, D. E. Horsman, R. D. Gascoyne, Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 11, 1065-1072 (2005).
25. S. L. Barrans, J. A. Fenton, A. Banham, R. G. Owen, A. S. Jack, Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104, 2933-2935 (2004).
26. M. van Keimpema, L. J. Grüneberg, M. Mokry, R. van Boxtel, J. Koster, P. J. Coffer, S. T. Pals, M. Spaargaren, FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood 124, 3431-3440 (2014).
27. S. W. Chang, M. Mislankar, C. Misra, N. Huang, D. G. Dajusta, S. M. Harrison, K. L. McBride, L. A. Baker, V. Garg, Genetic abnormalities in FOXP1 are associated with congenital heart defects. Hum. Mutat. 34, 1226-1230 (2013).
28. B. J. O'Roak, P. Deriziotis, C. Lee, L. Vives, J. J. Schwartz, S. Girirajan, E. Karakoc, A. P. Mackenzie, S. B. Ng, C. Baker, M. J. Rieder, D. A. Nickerson, R. Bernier, S. E. Fisher, J. Shendure, E. E. Eichler, Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 43, 585-589 (2011).
29. T. Lu, M. W. Jackson, A. D. Singhi, E. S. Kandel, M. Yang, Y. Zhang, A. V. Gudkov, G. R. Stark, Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NF-κB. Proc. Natl. Acad. Sci. U.S.A. 106, 16339-16344 (2009).
30. M. Ranzani, S. Annunziato, D. J. Adams, E. Montini, Cancer gene discovery: Exploiting insertional mutagenesis. Mol. Cancer Res. 11, 1141-1158 (2013).
31. M. E. Sowa, E. J. Bennett, S. P. Gygi, J. W. Harper, Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403 (2009).
32. S. M. Huang, Y. M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G. A. Michaud, O. Charlat, E. Wiellette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C. J. Wilson, C. Mickanin, V. Myer, A. Fazal, R. Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, S. Ghidelli, S. Fawell, C. Lu, D. Curtis, M.W. Kirschner, C. Lengauer, P. M. Finan, J. A. Tallarico, T. Bouwmeester, J. A. Porter, A. Bauer, F. Cong, Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
33. K. D. Proffitt, B. Madan, Z. Ke, V. Pendharkar, L. Ding, M. A. Lee, R. N. Hannoush, D. M. Virshup, Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res. 73, 502-507 (2013).
34. G. M. Kelly, P. Greenstein, D. F. Erezyilmaz, R. T. Moon, Zebrafish wnt8 and wnt8b share a common activity but are involved in distinct developmental pathways. Development 121, 1787-1799 (1995).
35. V. Quesada, L. Conde, N. Villamor, G. R. Ordóñez, P. Jares, L. Bassaganyas, A. J. Ramsay, S. Beà, M. Pinyol, A. Martinez-Trillos, M. López-Guerra, D. Colomer, A. Navarro, T. Baumann, M. Aymerich, M. Rozman, J. Delgado, E. Giné, J. M. Hernández, M. González-Díaz, D. A. Puente, G. Velasco, J. M. Freije, J. M. Tubío, R. Royo, J. L. Gelpí, M.Orozco, D. G. Pisano, J. Zamora, M. Vázquez, A. Valencia, H. Himmelbauer, M. Bayés, S. Heath, M. Gut, I. Gut, X. Estivill, A. López-Guillermo, X. S. Puente, E. Campo, C. López-Otín, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2012).
36. W. Zhang, S. C. Glöckner, M. Guo, E. O. Machida, D. H. Wang, H. Easwaran, L. Van Neste, J. G. Herman, K. E. Schuebel, D. N. Watkins, N. Ahuja, S. B. Baylin, Epigenetic inactivation of the canonicalWnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 68, 2764-2772 (2008).
37. K. H. Emami, C. Nguyen, H.Ma, D. H. Kim, K. W. Jeong, M. Eguchi, R. T. Moon, J. L. Teo, H. Y. Kim, S. H. Moon, J. R. Ha, M. Kahn, A small molecule inhibitor of β-catenin/ CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. U.S.A. 101, 12682-12687 (2004).
38. P. M. Evans, X. Chen, W. Zhang, C. Liu, KLF4 interacts with β-catenin/TCF4 and blocks p300/CBP recruitment by β-catenin. Mol. Cell. Biol. 30, 372-381 (2010).
39. L. Lévy, Y. Wei, C. Labalette, Y. Wu, C. A. Renard, M. A. Buendia, C. Neuveut, Acetylation of β-catenin by p300 regulates β-catenin-Tcf4 interaction. Mol. Cell. Biol. 24, 3404-3414 (2004).
40. S. Heinz, C. Benner, N. Spann, E. Bertolino, Y. C. Lin, P. Laslo, J. X. Cheng, C. Murre, H. Singh, C. K. Glass, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
41. A. Favorov, L. Mularoni, L. M. Cope, Y. Medvedeva, A. A. Mironov, V. J. Makeev, S. J. Wheelan, Exploring massive, genome scale datasets with the GenometriCorr package. PLOS Comput. Biol. 8, e1002529 (2012).
42. S. Frietze, R. Wang, L. Yao, Y. G. Tak, Z. Ye, M. Gaddis, H. Witt, P. J. Farnham, V. X. Jin, Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3. Genome Biol. 13, R52 (2012).
43. K. K. Wong, D. M. Gascoyne, P. J. Brown, E. J. Soilleux, C. Snell, H. Chen, L. Lyne, C. H. Lawrie, R. D. Gascoyne, L. M. Pedersen, M. B. Moller, K. Pulford, D. Murphy, T. M. Green, A. H. Banham, Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia 28, 362-372 (2013).
44. X. Ge, X. Lv, L. Feng, X. Liu, X. Wang, High expression and nuclear localization of β-catenin in diffuse large B-cell lymphoma. Mol. Med. Rep. 5, 1433-1437 (2012).
45. K. T. Pate, C. Stringari, S. Sprowl-Tanio, K. Wang, T. TeSlaa, N. P. Hoverter, M. M. McQuade, C. Garner, M. A. Digman, M. A. Teitell, R. A. Edwards, E. Gratton, M. L. Waterman, Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J. 33, 1454-1473 (2014).
46. S. Li, J. Weidenfeld, E. E. Morrisey, Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol. Cell. Biol. 24, 809-822 (2004).
47. J. W. Friedberg, Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011, 498-505 (2011).
48. F. J. Staal, J. Meeldijk, P. Moerer, P. Jay, B. C. van de Weerdt, S. Vainio, G. P. Nolan, H. Clevers, Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur. J. Immunol. 31, 285-293 (2001).
49. T. Reya, M. O'Riordan, R. Okamura, E. Devaney, K. Willert, R. Nusse, R. Grosschedl, Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 13, 15-24 (2000).
50. Y. W. Qiang, Y. Endo, J. S. Rubin, S. Rudikoff, Wnt signaling in B-cell neoplasia. Oncogene 22, 1536-1545 (2003).
51. R. Koch, M. Demant, T. Aung, N. Diering, A. Cicholas, B. Chapuy, D. Wenzel, M. Lahmann, A. Güntsch, C. Kiecke, S. Becker, T. Hupfeld, V. Venkataramani, M. Ziepert, L. Opitz, W. Klapper, L. Trümper, G. G. Wulf, Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood 123, 2189-2198 (2014).
52. S. Koivula, E. Valo, A. Raunio, S. Hautaniemi, S. Leppä, Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. Oncol. Rep. 25, 1183-1190 (2011).
53. P. Gelebart, M. Anand, H. Armanious, A. C. Peters, J. Dien Bard, H. M. Amin, R. Lai, Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 112, 5171-5179 (2008).
54. Y. Kimura, F. Arakawa, J. Kiyasu, H. Miyoshi, M. Yoshida, A. Ichikawa, D. Niino, Y. Sugita, T. Okamura, A. Doi, K. Yasuda, K. Tashiro, S. Kuhara, K. Ohshima, The Wnt signaling pathway and mitotic regulators in the initiation and evolution of mantle cell lymphoma: Gene expression analysis. Int. J. Oncol. 43, 457-468 (2013).
55. M. Mani, D. E. Carrasco, Y. Zhang, K. Takada, M. E. Gatt, J. Dutta-Simmons, H. Ikeda, F. Diaz-Griffero, V. Pena-Cruz, M. Bertagnolli, L. L. Myeroff, S. D. Markowitz, K. C. Anderson, D. R. Carrasco, BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 69, 7577-7586 (2009).
56. K. Takada, D. Zhu, G. H. Bird, K. Sukhdeo, J. J. Zhao, M. Mani, M. Lemieux, D. E. Carrasco, J. Ryan, D. Horst, M. Fulciniti, N. C. Munshi, W. Xu, A. L. Kung, R. A. Shivdasani, L. D. Walensky, D. R. Carrasco, Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med. 4, 148ra117 (2012).
57. T. Shigekawa, N. Ijichi, K. Ikeda, K. Horie-Inoue, C. Shimizu, S. Saji, K. Aogi, H. Tsuda, A. Osaki, T. Saeki, S. Inoue, FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm. Cancer 2, 286-297 (2011).
58. A. Giatromanolaki, M. I. Koukourakis, E. Sivridis, K. C. Gatter, A. L. Harris, A. H. Banham, Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: Relationship with estrogen receptors and HIF-1α expression. Mod. Pathol. 19, 9-16 (2006).
59. M. Nager, D. Bhardwaj, C. Canti, L. Medina, P. Nogues, J. Herreros, β-Catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother. Res. Practice 2012, 192362 (2012).
60. N. Zhang, P. Wei, A. Gong, W. T. Chiu, H. T. Lee, H. Colman, H. Huang, J. Xue, M. Liu, Y. Wang, R. Sawaya, K. Xie, W. K. Yung, R. H. Medema, X. He, S. Huang, FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20, 427-442 (2011).
61. G. G. Gomez, S. Volinia, C. M. Croce, C. Zanca, M. Li, R. Emnett, D. H. Gutmann, C. W. Brennan, F. B. Furnari, W. K. Cavenee, Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res. 74, 1429-1439 (2014).
62. F. F. Hamdan, H. Daoud, D. Rochefort, A. Piton, J. Gauthier, M. Langlois, G. Foomani, S. Dobrzeniecka, M. O. Krebs, R. Joober, R. G. Lafrenière, J. C. Lacaille, L. Mottron, P. Drapeau, M. H. Beauchamp, M. S. Phillips, E. Fombonne, G. A. Rouleau, J. L. Michaud, De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. Am. J. Hum. Genet. 87, 671-678 (2010).
63. C. Bacon, G. A. Rappold, The distinct and overlapping phenotypic spectra of FOXP1 and FOXP2 in cognitive disorders. Hum. Genet. 131, 1687-1698 (2012).
64. I. Iossifov, B. J. O'Roak, S. J. Sanders, M. Ronemus, N. Krumm, D. Levy, H. A. Stessman, K. T. Witherspoon, L. Vives, K. E. Patterson, J. D. Smith, B. Paeper, D. A. Nickerson, J. Dea, S. Dong, L. E. Gonzalez, J. D. Mandell, S. M. Mane, M. T. Murtha, C. A. Sullivan, M. F. Walker, Z. Waqar, L. Wei, A. J. Willsey, B. Yamrom, Y. H. Lee, E. Grabowska, E. Dalkic, Z. Wang, S. Marks, P. Andrews, A. Leotta, J. Kendall, I. Hakker, J. Rosenbaum, B. Ma, L. Rodgers, J. Troge, G. Narzisi, S. Yoon, M. C. Schatz, K. Ye, W. R. McCombie, J. Shendure, E. E. Eichler, M. W. State, M. Wigler, The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216-221 (2014).
65. C. Bacon, M. Schneider, C. Le Magueresse, H. Froehlich, C. Sticht, C. Gluch, H. Monyer, G. A. Rappold, Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour. Mol. Psychiatry 10.1038/mp.2014.116 (2014).
66. P. J. Brown, S. L. Ashe, E. Leich, C. Burek, S. Barrans, J. A. Fenton, A. S. Jack, K. Pulford, A. Rosenwald, A. H. Banham, Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111, 2816-2824 (2008).
67. M. R. Green, M. K. Gandhi, M. J. Courtney, P. Marlton, L. Griffiths, Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NF-κB activity in follicular lymphoma. Leuk. Res. 33, 1699-1702 (2009).
68. L. Rouhigharabaei, J. Finalet Ferreiro, T. Tousseyn, J. A. van der Krogt, N. Put, E. Haralambieva, C. Graux, B. Maes, C. Vicente, P. Vandenberghe, J. Cools, I.Wlodarska, Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. PLOS One 9, e85851 (2014).
69. T. L. Biechele, R. T. Moon, Assaying β-catenin/TCF transcription with β-catenin/TCF transcription-based reporter constructs. Methods Mol. Biol. 468, 99-110 (2008).
70. M. B. Major, N. D. Camp, J. D. Berndt, X. Yi, S. J. Goldenberg, C. Hubbert, T. L. Biechele, A. C. Gingras, N. Zheng, M. J. Maccoss, S. Angers, R. T. Moon, Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 316, 1043-1046 (2007).
71. D. K. Moss, A. Wilde, J. D. Lane, Dynamic release of nuclear RanGTP triggers TPX2-dependent microtubule assembly during the apoptotic execution phase. J. Cell Sci. 122, 644-655 (2009).
72. S. J. Deeb, R. C. D'Souza, J. Cox, M. Schmidt-Supprian, M. Mann, Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol. Cell. Proteomics 11, 77-89 (2012).
73. K. Walsh, M. S. McKinney, C. Love, Q. Liu, A. Fan, A. Patel, J. Smith, A. Beaven, D. D. Jima, S. S. Dave, PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin. Cancer Res. 19, 1106-1115 (2013).
74. B. E. Hast, D. Goldfarb, K. M. Mulvaney, M. A. Hast, P. F. Siesser, F. Yan, D. N. Hayes, M. B. Major, Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 73, 2199-2210 (2013).
75. A. L. Couzens, J. D. Knight, M. J. Kean, G. Teo, A. Weiss, W. H. Dunham, Z. Y. Lin, R. D. Bagshaw, F. Sicheri, T. Pawson, J. L. Wrana, H. Choi, A. C. Gingras, Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci. Signal. 6, rs15 (2013).
76. G. Weidinger, C. J. Thorpe, K. Wuennenberg-Stapleton, J. Ngai, R. T. Moon, The Sp1-related transcription factors sp5 and sp5-like act downstream of Wnt/β-catenin signaling in mesoderm and neuroectoderm patterning. Curr. Biol. 15, 489-500 (2005).
77. G. Özhan, E. Sezgin, D.Wehner, A. S. Pfister, S. J. Kuhl, B. Kagermeier-Schenk, M. Kuhl, P. Schwille, G. Weidinger, Lypd6 enhances Wnt/β-catenin signaling by promoting Lrp6 phosphorylation in raft plasma membrane domains. Dev. Cell 26, 331-345 (2013).
78. N. Shimizu, K. Kawakami, T. Ishitani, Visualization and exploration of Tcf/Lef function using a highly responsive Wnt/β-catenin signaling-reporter transgenic zebrafish. Dev. Biol. 370, 71-85 (2012).
79. T. Jowett, L. Lettice, Whole-mount in situ hybridizations on zebrafish embryos using a mixture of digoxigenin-and fluorescein-labelled probes. Trends Genet. 10, 73-74 (1994).
80. R. I. Dorsky, L. C. Sheldahl, R. T. Moon, A transgenic Lef1/β-catenin-dependent reporter is expressed in spatially restricted domains throughout zebrafish development. Dev. Biol. 241, 229-237 (2002).
81. A. Untergasser, H. Nijveen, X. Rao, T. Bisseling, R. Geurts, J. A. Leunissen, Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35, W71-W74 (2007).
82. Y. Kuwahara, D. Wei, J. Durand, B. E. Weissman, SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters. Mol. Cancer Res. 11, 251-260 (2013).
83. A. P. Bhatt, P. M. Bhende, S. H. Sin, D. Roy, D. P. Dittmer, B. Damania, Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTORaddicted lymphomas. Blood 115, 4455-4463 (2010).
84. J. A. Vizcaíno, E. W. Deutsch, R. Wang, A. Csordas, F. Reisinger, D. Rios, J. A. Dianes, Z. Sun, T. Farrah, N. Bandeira, P. A. Binz, I. Xenarios, M. Eisenacher, G. Mayer, L. Gatto, A. Campos, R. J. Chalkley, H. J. Kraus, J. P. Albar, S. Martinez-Bartolomé, R. Apweiler, G. S. Omenn, L. Martens, A. R. Jones, H. Hermjakob, ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226 (2014).